Adaptimmune 
Welcome,         Profile    Billing    Logout  
 11 Products   26 Diseases  11 Products   12 Trials   545 News 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
letetresgene autoleucel (GSK3377794) / Adaptimmune
NCT05993299: Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Active, not recruiting
2
7
Europe, Canada, US
Letetresgene autoleucel, Cyclophosphamide, Fludarabine
GlaxoSmithKline
Neoplasms
10/22
07/24
IGNYTE-ESO, NCT03967223 / 2019-000415-87: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

Active, not recruiting
2
103
Europe, Canada, US
Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide
Adaptimmune
Neoplasms
09/24
07/26
2018-003949-42: A study of NY-ESO-1 T-cells (GSK3377794) alone and in combination with Pembrolizumab in NSCLC patients.

Not yet recruiting
1/2
54
Europe
GSK3377794, Pembrolizumab, GSK3377794, MK-3475, Dispersion for infusion, Solution for infusion, KEYTRUDA
GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, S.A., GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, S.A.
Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC), Non-Small Cell Lung Cancer (NSCLC), Diseases [C] - Cancer [C04]
 
 
ADP-A2AFP / Adaptimmune
NCT03132792: AFPᶜ³³²T in Advanced HCC

Active, not recruiting
1
45
Europe, US
Autologous genetically modified AFPᶜ³³²T cells
Adaptimmune
Hepatocellular Cancer, AFP Expressing Tumors
07/21
07/25
Tecelra (afamitresgene autoleucel) / Adaptimmune
2019-000589-39: Study to assess the safety and efficacy of T cell therapy in patients with advanced cancer

Not yet recruiting
2
60
Europe, RoW
ADP-A2M4, ADP-A2M4, Infusion
Adaptimmune LLC, Adaptimmune LLC
Synovial sarcoma, Myxoid round cell liposarcoma, Soft tissue cancer, Diseases [C] - Cancer [C04]
 
 
SPEARHEAD-1, NCT04044768: Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Oct 2022 - Jun 2023: BLA submission for treatment of synovial sarcoma
Checkmark Data from cohort 1 of SPEARHEAD-1 trial for synovial sarcoma or myxoid round cell liposarcoma
Nov 2022 - Nov 2022: Data from cohort 1 of SPEARHEAD-1 trial for synovial sarcoma or myxoid round cell liposarcoma
Checkmark Pooled analysis data from trials for sarcoma at AACR 2022
Jun 2022 - Jun 2022: Pooled analysis data from trials for sarcoma at AACR 2022
More
Recruiting
2
120
Europe, Canada, US
afamitresgene autoleucel (previously ADP-A2M4)
Adaptimmune
Synovial Sarcoma, Myxoid Liposarcoma
10/21
04/38
NCT05642455: SPEARHEAD-3 Pediatric Study

Recruiting
1/2
20
US
Afamitresgene autoleucel
Adaptimmune
Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma, Osteosarcoma
10/26
07/38
NCT03132922: MAGE-A4ᶜ¹º³²T for Multi-Tumor

Checkmark Pooled analysis data from trials for sarcoma at AACR 2022
Jun 2022 - Jun 2022: Pooled analysis data from trials for sarcoma at AACR 2022
Checkmark Clinical response data from SURPASS trial for solid tumors at CTOS 2019
Nov 2019 - Nov 2019: Clinical response data from SURPASS trial for solid tumors at CTOS 2019
Active, not recruiting
1
71
Canada, US
Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
Adaptimmune
Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Synovial Sarcoma, Myxoid Round Cell Liposarcoma, Gastroesophageal Junction
12/22
09/32
NCT06617572: Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel

Available
N/A
US
Non-conforming afamitresgene autoleucel
Adaptimmune
Synovial Sarcoma, Myxoid Liposarcoma
 
 
TC-110 / Adaptimmune
NCT04323657: TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Completed
1/2
6
US
TC-110 T Cells, Fludarabine, Cyclophosphamide
TCR2 Therapeutics
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
02/23
02/23
uzatresgene autoleucel (ADP-A2M4CD8) / Adaptimmune, Galapagos
2022-003176-16: This is a phase 2 open label clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in subjects with recurrent ovarian cancer Este es un ensayo clínico abierto de fase 2 para evaluar el resultado clínico de ADP A2M4CD8 como monoterapia y en tratamiento combinado connivolumab en pacientes con cáncer de ovario recurrente.

Not yet recruiting
2
66
Europe
ADP-A2M4CD8, OPDIVO (nivolumab), ADP-A2M4CD8, Dispersion for infusion, Concentrate for solution for infusion, OPDIVO (nivolumab)
Adaptimmune LLC, Adaptimmune LLC
Recurrent ovarian cancer positive for MAGE-A4 in human leukocyte antigen (HLA)-A2+ subjects Cáncer de ovario recurrente positivo para MAGE-A4 en sujetos con antígeno leucocitario humano (HLA)-A2+, Recurrent ovarian cancer Cáncer de ovario recurrente, Diseases [C] - Cancer [C04]
 
 
SURPASS-2, NCT04752358 / 2020-005802-24: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers

Terminated
2
3
Europe, Canada, US
Autologous genetically modified ADP-A2M4CD8 cells
Adaptimmune, ICON plc
Esophageal Cancer, Esophagogastric Junction Cancer
06/23
12/23
SURPASS-3, NCT05601752: ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer

Recruiting
2
66
Europe, Canada, US
Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
Adaptimmune, GOG Foundation
Ovarian Cancer
08/26
08/26
SURPASS, NCT04044859: ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors

Checkmark Results from SURPASS trial for MAGE-4 positive tumors
Sep 2022 - Sep 2022: Results from SURPASS trial for MAGE-4 positive tumors
Checkmark Clinical response data from SURPASS trial for solid tumors at CTOS 2019
Nov 2019 - Nov 2019: Clinical response data from SURPASS trial for solid tumors at CTOS 2019
Recruiting
1
120
Europe, Canada, US
Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
Adaptimmune, ICON plc
Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma, Ovarian Cancer, Non-small Cell Lung (NSCLC), Urothelial Cancer
12/25
04/37
gavocabtagene autoleucel (TC-210) / Adaptimmune
NCT03907852: Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Active, not recruiting
1/2
36
Canada, US
gavo-cel, fludarabine, cyclophosphamide, Nivolumab, Ipilimumab
TCR2 Therapeutics, Bristol-Myers Squibb
Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural, Mesothelioma Peritoneum, Cholangiocarcinoma, Cholangiocarcinoma Recurrent, Ovarian Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, High Grade Ovarian Serous Adenocarcinoma
11/28
11/28
GSK3901961 / Adaptimmune
NCT06048705: Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer

Terminated
1
7
Europe, Canada, US, RoW
GSK3901961, Cyclophosphamide, Fludarabine
GlaxoSmithKline
Neoplasms
06/23
06/23
ZENYTH-ESO, NCT04526509: Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Terminated
1
12
Europe, Canada, US, RoW
GSK3901961, GSK3845097, GSK4427296, Cyclophosphamide, Fludarabine
GlaxoSmithKline
Neoplasms
06/23
06/23
TC-510 / Adaptimmune
NCT05451849: A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Active, not recruiting
1/2
6
US
TC-510, Fludarabine, Cyclophosphamide
TCR2 Therapeutics
Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Ovarian Adenocarcinoma, Pancreatic Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma, Non Small Cell Lung Cancer
10/28
10/28
ADP-TILIL7 / Adaptimmune
ADP-TILIL7, NCT06204991: To Evaluate the Safety and Efficacy of in Patients With Locally Advanced or Metastatic Melanoma

Not yet recruiting
1
10
NA
ADP-TILIL7, Cyclophosphamide, Fludarabine Phosphate, Proleukin
Inge Marie Svane, Adaptimmune
Melanoma Stage III, Melanoma Stage IV, Melanoma
03/26
04/27

Download Options